The key discoveries that laid the foundations for CAR T cell therapies are summarized and a broad overview of the current principles of CAR design, their clinical development and emerging strategies aimed at enhancing efficacy, broadening indications and achieving durable immune control across disease types are provided.
Continued efforts to identify highly specific target antigens, optimize manufacturing processes, enhance safety, and integrate CAR-T therapy with complementary immunotherapeutic approaches are expected to improve clinical outcomes and broaden the application of CAR-T therapy to T-cell malignancies and potentially other...
H. Hetta, Fawaz E. Alanazi, Mahmoud H. El-Maghrabey et al.· Journal of Pharmaceutical In...· 0 citations
In vivo CAR-T is poised to broaden the reach of cellular immunotherapy, provided that its development is guided by rigorous pharmacology, chemistry, manufacturing and controls, and long-term molecular safety surveillance.
Wan-Ting Wang, Yujia Cai, Xuanming Yang et al.· Immunity & Inflammation· 0 citations
This review aims to provide a comprehensive overview of recent advances in the design of innovative CAR architectures to expand the targetable antigen landscape and discusses innovative CARs in four main categories.
Umida Yoziyeva, Alexey Yumashev, Shakhodat Kobilova et al.· Transplantation and Cellular...· 0 citations
Chimeric antigen receptor (CAR)-T cells are synthetic receptors used for the recognition of specific antigens expressed by reprogrammed T cells for targeting tumors. CAR-T cell therapy has gained remarkable clinical success for the treatment of hematological malignancies such as chronic lymphocytic leukemia (CLL), mant...
Qasim Javed, Shoaib Majeed, Adnan Shahid et al.· Anti-Cancer Agents in Medici...· 0 citations
If in-vivo CAR-T therapy approaches continue to mature, they may offer a more scalable, cost-effective, and accessible alternative to traditional ex vivo CAR-T therapy, though this remains a projected rather than demonstrated benefit.
Lia Bhatia· American Journal of Student...· 0 citations
Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.
Markus Barden, D. Harrer, Hinrich Abken· Expert Opinion on Biological...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
